Pharmacokinetics of Orally Administered Terbinafine in African Penguins (Spheniscus demersus) for Potential Treatment of Aspergillosis
Authors:
- Ursula BechertUBUrsula Bechert
- J. Mark ChristensenJCJ. Mark Christensen
- Robert PoppengaRPRobert Poppenga
- Hang LeHLHang Le
- Jeff WyattJWJeff Wyatt
- Todd SchmittTSTodd Schmitt
- 1 June 2010
- journal article
- clinical trial
- Published by American Association of Zoo Veterinarians in Journal of Zoo and Wildlife Medicine
- Vol. 41 (2) , 263-274
Abstract
The objective of this study was to determine the pharmacokinetic parameters of orally administered terbinafine hydrochloride based on 3, 7, and 15 mg/kg single- as well as multiple-dosage trials in order to calculate dosing requirements for potential treatment of aspergillosis in African penguins (Spheniscus demersus). Ten adult African penguins were used in each of these trials, with a 2-wk washout period between trials. Mean plasma concentrations of terbinafine peaked in approximately 4 hrs at 0.11 +/- 0.017 microg/ml (mean +/- SD) following administration of 3 mg/kg terbinafine, while 7 mg/kg and 15 mg/kg dosages resulted in peak plasma concentrations of 0.37 +/- 0.105 and 0.33 +/- 0.054 microg/ml, respectively. The volume of distribution increased with increasing dosages, being 37 +/- 28.5, 40 +/- 28.1, and 52 +/- 18.6 mg/L for 3, 7, and 15 mg/kg doses, respectively. The mean half-life was biphasic with initial terminal half-life (t(1/2)) values of 9.9 +/- 4.5, 17.2 +/- 4.9 and 16.9 +/- 5.4 hrs, for 3, 7, and 15 mg/kg doses, respectively. A rapid first elimination phase was followed by a slower second phase, and final elimination was estimated to be 136 +/- 9.7 and 131 +/- 9.9 hrs, for 7 and 15 mg/kg doses, respectively. Linearity was demonstrated for area under the curve but not for peak plasma concentrations for the three dosages used. Calculations based on pharmacokinetic parameter values indicate that a 15 mg/kg terbinafine q24h dosage regimen would result in steady-state trough plasma concentrations above the minimum inhibitory concentration (0.8-1.6 microg/ ml), and this dosage is recommended as a potential treatment option for aspergillosis in penguins. However, additional research is required to determine both treatment efficacy and safety.Keywords
This publication has 56 references indexed in Scilit:
- The Use of Voriconazole for the Treatment of Aspergillosis in Falcons (Falco Species)Journal of Avian Medicine and Surgery, 2007
- Update on antifungal drug resistance mechanisms of Aspergillus fumigatusDrug Resistance Updates, 2005
- Immunity toAspergillus fumigatus: the basis for immunotherapy and vaccinationMedical Mycology, 2005
- Combinations of antifungal agents in therapy–what value are they?Journal of Antimicrobial Chemotherapy, 2004
- Systemic Aspergillosis in an Oiled Magallanic Penguin (Spheniscus magellanicus)Journal of Veterinary Medicine, Series B, 2001
- Pharmacokinetics of Antifungal Agents in OnychomycosesClinical Pharmacokinetics, 2001
- In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicansJournal of Antimicrobial Chemotherapy, 1998
- Determination of terbinafine and its desmethyl metabolite in human plasma by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- TerbinafineDrugs, 1992
- Azoles and allylamines: the clinical implications of interaction with cytochrome P-450 enzymesJournal of Dermatological Treatment, 1990